Thursday, 16 August 2012

ReportsnReports - Packaging Industry in the Netherlands

Discover the latest market trends and uncover sources of future market growth for the Packaging industry in Netherlands with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Packaging industry in Netherlands, our research will save you time and money while empowering you to make informed, profitable decisions.

The Packaging in Netherlands market research report includes:
  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volumes and values, company and brand market shares
  • Five year forecasts of market trends and market growth
  • Robust and transparent market research methodology, conducted in-country
Our market research reports answer questions such as:
  • What is the retail unit volume of the packaging market in Netherlands?
  • What are the major pack types and how are they performing in Netherlands?
  • Have there been any packaging legislative changes over the past 12 months?
  • How has the packaging industry been affected by the recession?
  • How are consumption trends impacting the packaging landscape?
  • What have been the key trends seen in new packaging developments?
  • How important is sustainability in packaging to consumers in Netherlands?
Why buy this report?
  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions
This industry report originates from Passport, our Packaging market research database.

SAMPLE ANALYSIS

EXECUTIVE SUMMARY

On-the-go retail outlets favour healthy trend


An important development for the packaging industry in the Netherlands is the growth of on-the-go retailers such as AH to go, from Albert Heijn. These retailers, which are generally located at railway stations and business centres and offer longer opening hours, continued to grow in importance in 2011, and embody the overall new consumer trend of custom-made convenient 1-bite/drink-and-go packaging. Products are often more expensive and are marketed as premium. Brands available in these outlets are consumed more frequently, resulting in a boost in small-sized and often wide-margin impulse food packaging. Increasing attention is paid to the quality of to-go food and beverages. 100% fruit juices are in high demand in these outlets, alongside premium food.

Pouches become a new standard pack type
Pouches are increasingly becoming a new standard pack type across the board. A lot of the trends evident are actively enhanced by pouches, and it is therefore a convenient new pack type, especially for large industrial players such as Unilever, PepsiCo and Mars: In wet cat food alone, pouches gained 10 million units over 2011, representing fierce competition to metal food cans and even aluminium trays. The pouch enables a greater perception of the product as being fresh and of high quality, while increasing consumption frequency as it offers single-portion sizes.

Trading up and downsizing

Quality of products is increasingly important in the Netherlands as pack sizes are getting smaller, with noticeable unit growth for juice in 250ml brick liquid cartons and glass bottles illustrating this trend in 2011. The perception of quality and convenience is here to compensate for a decrease in overall content per pack and quantity of product. Packaging has an important role in selling this deal to the customer. In the Netherlands packagers are increasingly successful in doing so with help of their retail and production compatriots. By making packaging to the specific needs of the customer, in certain circumstances they are allowed to play with pack sizes, leaving a more diverse packaging landscape.

Heineken does it again
Faithful to a tradition of differentiation through packaging, Dutch beer brand owner Heineken has chosen to reinvent the keg, this time the plastic version. The proactive search for brand strength through packaging innovation has proven most useful to the Heineken brand with the introduction of the 4-litre home minikeg. The plastic based, other rigid container offers consumers an alternative to the heavier to carry, metallic keg, also claimed to be easier to use. The product saw a reasonably good performance over 2011, as the Dutch were willing to give the keg concept another go so as to consume beer more in group gathering while the pack type also fits well with the ever growing cocooning trend; whereby consumers spend less in foodservice and more in retail for a more affordable, home consumption.

Get your copy of this reports @ http://www.reportsnreports.com/reports/185085-packaging-industry-in-the-netherlands.html

Report Details:

Published: August 2012
Price : Single User License: US$ 1900                   
Request Sample


Packaged Food Ingredients: Regional Insights: ReportsnReports

Regional variations in packaged food demand can be quite considerable and this has significant implications for ingredients supply. This report provides an overview of the market for packaged food ingredients, with particular reference to the differing needs of different regions around the world, examining key trends and developments in each of the seven major continental areas and highlighting the best opportunities for future growth.

Euromonitor International's Packaged Food Ingredients: Regional Insights global briefing offers a comprehensive guide to the Ingredients market at an international level. It highlights the major drivers behind ingredient supply and demand, provides detailed analysis of the individual ingredient categories and the product categories they are used in.  It also examines regional prospects, highlighting opportunities and challenges in ingredient usage.

Product coverage: Abrasives/Inorganics, Acidulants, Antifoams, Antifungals, Antimicrobials, Antiperspirants, Bleach Precursors, Bleaching Agents, Botanicals, Carotenoids, Cocoa Liquor, Cocoa Powder, Colours, Commodities, Conditioning Agents (Skin, Hair, Fabric), Cultures, Emollients, Emulsifiers and Co-Emulsifiers, Enzymes, Fats and Oils, Flavour Enhancers, Flavours, Flours, Fluorescers, Fragrances, Humectants, Insect Repellants, Insecticides, Lacquers, Milk, Minerals, Miscellaneous Ingredients, Modified Flour, pH Control/salts, Phytoestrogens, Polysaccharides and Oligosaccharides, Preservatives/Antioxidants, Propellants, Proteins, Raising Agents, Reducing Agents, Skin Benefit Agents, Skin Lighteners, Skin Tanning Agents, Solvents, Sunscreens, Surfactant Cleansers and Adjuvants, Sweeteners, Synthetic Polymers, Thickeners/Structurants, Tooth Care, Vitamins and Derivatives, Water Softeners/Chelators.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?
  • Get a detailed picture of the Ingredients market;
  • Pinpoint growth sectors and identify factors driving change;
  • Understand the competitive environment, the market’s major players and leading brands;
  • Use five-year forecasts to assess how the market is predicted to develop.
Euromonitor International has over 40 years' experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town, Santiago, Sydney, Tokyo and Bangalore and a network of over 800 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.

Get your copy of this reports @ http://www.reportsnreports.com/reports/185080-packaged-food-ingredients-regional-insights.html

Report Details:

Published: August 2012
No. of Pages: 50
Price : Single User License: US$ 2000                   
Request Sample

Wednesday, 8 August 2012

The Global Military Radar Market 2012–2022 - Country Analysis: Market Profile

Synopsis
This report offers detailed analysis of the global Military Radar market over the next ten years, and provides extensive market size forecasts by country and sub sector. It covers the key technological and market trends in the Military Radar market.

Summary
Global Military Radar market-country analysis provides details of the key markets in each region, offering an analysis of the top segments of Military Radar, expected to be in demand. It also investigates the top three expected Military Radar programs, in terms of demand in the key markets in each region.

Reasons To Buy
"The Global Military Radar Market 2012–2022 - Country Analysis" allows you to:

• Have access to a detailed analysis of defense spending patterns including forecasts of Military Radar spending till 2021 by region.
• Gain insight into various defense modernization initiatives around the world.
• Obtain detailed information on leading Military Radar programs of major defense spenders across the world.
• Gain insight into sub-sector markets with comprehensive market values and forecasts of the leading defense spending nations.



Report Details:
Published: August 2012
No. of Pages: 88
Price : Single User License: US$ 2950                    Price : Corporate User License: US$ 8850
Request Sample

Friday, 3 August 2012

Global IVD Tests Industry & US In Vitro Diagnostics Market Forecast to 2016


ReportsnReports.com adds two brand new market research reports on the In Vitro Diagnostics Industry covering The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 8th Edition as well as US In Vitro Diagnostics to 2016.
This study on In Vitro Diagnostics, priced at $5100, presents historical demand data for 2001, 2006 and 2011, as well as forecasts for 2016 and 2021 by product, application, and market. This study also considers key market environment factors, evaluates company market share, and profiles 27 competitors in the US IVD industry.
IVD demand in US to reach nearly $25 billion in 2016
US demand for in vitro diagnostic (IVD) products will rise more than six percent annually to nearly $25 billion in 2016. Aging demographic patterns, expanding levels of health insurance coverages, and new product introductions will underlie gains. Growth in the middle aged and elderly population segments will boost overall health care needs, leading to a rising volume of IVD tests. The extension of health insurance coverage attributable to the Affordable Health Care Act of 2010 will make basic and specialized IVD procedures available to a greater number of individuals. Advances in cellular analysis, molecular diagnostic and other advanced technologies will expand applications for IVD products in disease detection, forensic medical, and identity testing.
Clinical chemistry, immunoassay to remain top products
Clinical chemistry and immunoassay will remain the top two IVD methodologies, the former based on sales of personal blood glucose monitors and test strips and the latter due to the penetration of high value-added chemiluminescent products into infectious disease and drug testing markets. Molecular diagnostic products will post the fastest growth in demand among all IVD products based on throughput, accuracy, and speed advantages, especially in the detection of infectious diseases and cancer markers. Diabetes testing will remain the largest IVD application through 2016 and beyond due to increasing blood glucose monitoring among afflicted patients.
Hemostasis tests for cardiac conditions offer best growth
Based on their ability to quantify heart attack and embolism risk prior to occurrence, hemostasis tests for D-dimer and other cardiac parameters will command the best growth among IVD blood testing products. Demand for molecular diagnostic products will expand at a strong pace as next-generation PCR (polymerase chain reaction) and FISH (fluorescence in situ hybridization) penetrate applications involving the analysis, characterization, and therapeutic monitoring of complex infections and tumors. DNA-based forensic, genetic, and identity testing will comprise one of the fastest growing IVD applications through 2016 as the vast potential of law enforcement and genetic screening markets begins to translate into significant revenues. Among other IVD products, cellular analysis and anatomical pathology reagents and instruments will post the best sales gains. Cellular analysis techniques will continue to dominate cervical cancer testing and penetrate additional cancer diagnostic applications. Anatomical pathology will remain the leading IVD technique for biopsy-based cancer and infectious disease detection.
Diabetes testing to benefit clinical chemistry reagents & instruments
Evolving epidemiological trends and patient care approaches will impact favorably on growth opportunities for most types of IVD products. The market for clinical chemistry reagents and instruments will benefit from an increasing number of diabetic patients engaging in self-blood glucose monitoring and the expanding use of general health screening in routine patient examinations. The widening availability of chemiluminescent tests with inherent sensitivity and selectivity advantages will broaden applications for immunoassays in therapeutic drug monitoring, drugs of abuse detection, and infectious disease testing.
Explore Table of Contents, Request A Sample for purchase consideration or Buy your copy of this report @: http://www.reportsnreports.com/reports/183965-in-vitro-diagnostics-to-2016.html
This edition features a demonstrative increase of hundreds of pages from the 2010 edition as new companies have entered the diagnostic market and IT companies make their mark on diagnostics.

Comprehensive Coverage of a High Interest Industry
The report is over 1400 pages, reflecting the dramatic change in IVD.  New entrants, net technologies have entered the stage and all important events are cataloged in this report.  The idea behind this unique report is that the entire market can be captured in one volume and business planners avoid multiple purchases. Published every two years, this volume includes coverage of the most important aspects of all of the major segments of clinical lab testing, including:
  • Point of Care (POC), (Professional and Self-Testing)
  • Histology and Cytology (Pap, ISH, IHC, traditional non-pap, HPV)
  • Core Lab (General Chemistries, Workstations, Analyzers)
  • Immunoassays (Blood Gases, Urinalysis, Critical Care)
  • Molecular Assays (Infectious Disease, Blood Screening, Inherited Diseases, Oncology, Pharmacodiagnostics, Tissue Typing, Prenatal)
  • Hematology
  • Coagulation (Lab-Based, POC, Genetic Markers)
  • Microbiology and Virology
  • Blood Banking (Grouping, Immunoassay Screens, NAT Screens)

Market sizes, forecasts and shares are provided, as well as a geographic breakdown of the segments, where possible. Changes in technology development, regulatory and reimbursement issues, clinical care, and business environments are discussed. Current market numbers are presented for 2011, with projections given through 2016.

The "Bible of the IVD Industry"
Now in 8 editions, this report has become the go-to market research reference for the industry.  Many of the top IVD companies use this product for business planning, which means that this volume can provide a uniform standard for in vitro diagnostic market numbers. This edition greatly expands coverage of the field and tracks the most important developments.  See aspects of the industry that might not be available in your company's internal resources.  View the market from an independent point of view.  Learn about competitors in away that may be invisible to internal personnel.  Know the market players - your competitors and potential partners, in proper context and classification.  Save countless hours of staff time and other research expenses with the authoritative guide for IVD market estimates and forecasts.

A Global Report
From the first edition, this report was designed as a global resource in order to give market-watchers a true picture of the industry.  IVD is a worldwide business. While the US is a large healthcare market, much of the dynamism, the growth, and also competition is occurring in other areas. Many of the most interesting opportunities for companies are occurring in emerging markets. As part of its coverage, the report breaks down the entire IVD market for the following regions: North America, Europe (EU countries, incl. IVD market sizes by country), Eastern Europe, South America, Asia (Japan, China and India) and Rest of World.

A Report Designed for a Changing Industry
A number of totally disparate phenomena have come together to change the IVD industry. Human genome research is finding links between a person’s genome and several lifestyle situations such as nutrition, dieting, skin conditions and other essentially non-medical conditions. This has attracted consumer product companies such as Proctor & Gamble and Nestlé to develop products and services based on IVD technologies. Decreases in life science grants have encouraged companies active in this space to migrate their technologies for clinical applications.

 The result is the entry of companies such as Caliper Life Sciences, Illumina, Affymetrix and Life Technologies to the diagnostics market with products and test services. Miniaturization of traditional immunoassay and molecular test technologies has finally matured to the point where they may be ready for scale-up and then commercialization into products. Here electronics companies such as Sony, Samsung, Dell Computers and Intel Corp. have invested in clinical diagnostics ventures. These exciting developments join expansion into new market segments by companies already involved in the IVD industry.

In 2010 and 2011, there were at least 74 acquisitions and some 36 distribution agreements. And this is only a small portion of what is really happening. There are many more deals that have not been announced. The goal is to build better tests and stronger companies. The future of the industry lies in the development of more sensitive, faster, user-friendly, IT capable devices for a host of new protein and molecular markers.

In this eighth edition of The Worldwide Market for In Vitro Diagnostic Tests Kalorama Information addresses all of the key issues affecting the diagnostic industry in 2012 and how competitors are faring. Among the topics tackled in this report:

Molecular diagnostics including infectious disease mdx, pharmacodiagnostics, molecular poc and test services are put in a context.
  • Merging IT and IVD: Establishing the EMR Record from IVD Tests
  • Healthcare Reform and its Possible Impact on IVD.
  • The Status of Automation in the Lab; Core Lab Section Includes Both Workstation and Automated Panel Revenues.
  • Mass Spec, Next Gen Sequencing and Other Technology Entrants
  • Hospital Infection Testing - the latest
  • Several Hundred Company profiles. Top tier companies, Second and Third Tier companies but also Smaller Innovators. The report‘s profiles distinguish between companies that are leaders in all aspects of IVD, those that are Specialists in one particular area or a few.
  • Major Mergers as well as Partnerships, Distribution Agreements.
  • Brazil, India and China - Important Emerging Markets for IVD.  
  • Innovations in Blood Banking
  • Histology/Cytology innovations; the role of FISH testing and Digital Images
  • Healthcare statistics for various countries -healthcare spending as a percent of GDP, new hospitals, cost increases and other information.
  • Tables that document the most competitive products on the market and under development in each area of IVD.
  • Country-level Breakout of IVD market for major European and Asian countries.
  • The Current Economic Situation
  • Update on the Regulation of Novel Devices

Explore Table of Contents, Request A Sample for purchase consideration or Buy your copy of this report @: http://www.reportsnreports.com/reports/183811-the-worldwide-market-for-in-vitro-diagnostic-ivd-tests-8th-edition.html
You may also be interested in other reports on the Biotechnology Market available @ http://www.reportsnreports.com/market-research/biotechnology/
Contact sales@reportsandreports.com for further information or for your specific requirements.

Thursday, 2 August 2012

Markets for Electrostimulation Devices (Neurostimulation, Cardiac Rhythm Management, Fracture Healing and Others)



Electrical and magnetic stimulation is the primary focus of this Kalorama Information Report. Rather than attempting to define and classify all of the varying electro stimulatory methods, this report groups technologies into basic categories based on application and complexity.

The audience for this report includes technical directors, business development managers, investors, and analyst’s who want a panoramic view, at a quantitative level, of the technology and medical applications of electrical and magnetic stimulation. This is a far-reaching field, and this report thus serves as a survey aimed at providing insight about the realm of market possibilities.  Two general segments are discussed with various sub-segments included:

External Electrical Stimulation Devices:
  • Bone Growth Simulation
  • Transcutaneous Electrical Nerve Stimulation (TENS)
  • Ultrasound-Accelerated Fracture Healing
Implanted Electrical Simulation Devices
  • Bone Growth Stimulation
  • Cardiac Resynchronization Therapy
  • Deep Brain Stimulation
  • Gastric Electrical Stimulation
  • Implantable Cardiac Pacemakers
  • Implantable Cardioverter-Defibrillators
  • Sacral Nerve Stimulation
  • Spinal Cord Stimulation
  • Vagus Nerve Stimulation
Companies involved in the market are profiled to provide an understanding of today’s competitive environment and marketing strategies.

Demand for both electrical and magnetic neurostimulation technologies is expected to grow moderately during the next few years.

TENS is commonly used for pain management. Despite controversy over the degree to which TENS is more effective than placebo in reducing pain, the market for TENS equipment continues to remain steady. Electro muscular stimulation (EMS) of muscle tissue can aid in the recuperation of overworked muscles. Technological progress continues in EMS, especially with microprocessors that allow protection against the risk of burning and elimination of electrical pain. Transcranial magnetic stimulation (TMS) is a non-invasive technique that uses an electromagnet placed on the patient’s scalp to alter brain activity. Repetitive TMS (rTMS), which uses varying frequencies and intensities of magnetic fields, seems to have therapeutic value. During the previous years, rTMS has received a growing attention in the popular and scientific media. The market forecasts reflect growing professional medical acceptance. The demand of electro stimulation products based on external electrodes is expected to benefit from innovative developments in FES designed to augment movement of atrophied muscles, promote new nerve function, and provide interfaces between nerve cells and computing devices. The market for treating depression is one of the most promising applications of neurotechnology devices. The potential market opportunity is huge, with between over 20 million people in the U.S.alone who could potentially benefit.

A new group of active electrodes are underdevelopment. These can connect nerve cells to microcircuits and provide aliving link between living tissues and hardware. Direct interfaces between small networks of nerve cells and micro devices are advancing the understanding of nerves and leading the way to a new generation of hybrid devices that communicate between computers and biological neural networks. There are several research teams in the U.S.and Europe that are currently working onso-called neural-silicon hybrid chips. Wireless technology could lead to the replacement of leads with small radios that can transmit and receive information and energy.

Companies Profiled in this report include:
  • Amrex Electrotherapy Equipment (Division of Amrex-Zetron)
  • Biomet, Inc.
  • Bioness, Inc.
  • Boston Scientific, Inc
  • Cyberonics, INC
  • Delsys, INC
  • DJO International
  • Dynatronics Corporation
  • Electromedical Products International (EPI)
  • Magstim Company, Ltd.
  • MedFaxx., INC
  • Medtronic, INC
  • Multi radiance Medical, Inc
  • Neuronetics, Inc
  • Noraxon USA, Inc
  • Orthofix International NV
  • Prizm Medical, Inc.
  • Rich-Mar Corporation
  • RS Medical
  • Smith & Nephew
  • Somatics, LLC
  • St Jude Medical, Inc.
  • Thought Technology Ltd.

Report Details:
Published: July 2012
No. of Pages: 198
Price : Single User License: US$ 3995                    Price : Corporate User License: US$ 7990
Request Sample

    Wednesday, 1 August 2012

    Architecture, Engineering and Construction Software and Services Market in the EMEA Region 2011-2015

    TechNavio's analysts forecast the AEC Software and Services market in the EMEA region to grow at a CAGR of 7.6 percent over the period 2011-2015. One of the key factors contributing to this market growth is the use of the Go-Green concept in the AEC industry. The AEC Software and Services market in the EMEA region has also been witnessing the use of digital signatures in the AEC industry. However, the lack of interoperability could pose a challenge to the growth of this market.
    TechNavio's report, the Architecture, Engineering and Construction Software and Services Market in the EMEA Region 2011-2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report focuses on the EMEA region; it also covers the AEC Software and Services market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
    Key vendors dominating this market space include Autodesk Inc., Aveva Group plc, Bentley Systems Inc. and Nemetschek AG. Other vendors mentioned in the report: Intergraph Corp. and Tekla Corp.
    Key questions answered in this report:
    • What will the market size be in 2015 and at what rate will it grow?
    • What key trends is this market subject to?
    • What is driving this market?
    • What are the challenges to market growth?
    • Who are the key vendors in this market space?
    • What are the opportunities and threats faced by each of these key vendors?
    • What are the strengths and weaknesses of each of these key vendors?

    Buy your copy of this report @ http://www.reportsnreports.com/reports/182723-architecture-engineering-and-construction-software-and-services-market-in-the-emea-region-2011-2015.html


    Report Details:
    Published: July 2012
    No. of Pages: 35
    Price: Single User License – US$1500             Corporate User License – US$2500
                                                       Request Sample

    Table of Contents
    1. Executive Summary
    2. Introduction
    3. Market Coverage
    Market Overview
    Key Offerings
    4. Market Landscape
    Market Forecast
    AEC Software Segment in the EMEA Region
    AEC Services Segment in the EMEA Region
    4.1 Five Forces Analysis
    5. Vendor Landscape
    6. Market Growth Drivers
    7. Drivers and their Impact
    8. Market Challenges
    9. Impact of Drivers and Challenges
    10. Market Trends
    11. Key Vendor Analysis
    11.1 Nemetschek AG
    Business Overview
    SWOT Analysis
    11.2 Autodesk Inc.
    Business Overview
    SWOT Analysis
    11.3 Bentley Systems Inc.
    Business Overview
    SWOT Analysis
    11.4 Aveva Group plc
    Business Overview
    SWOT Analysis
    12. Other Reports in this Series
    List of Exhibits
    Exhibit 1: Architecture, Engineering and Construction Software and Services Market in the EMEA Region 2011-2015 (US$ billion)
    Exhibit 2: Comparison of Growth of Architecture, Engineering and Construction Software and Services Market in the EMEA Region and Rest of the World 2011-2015
    Exhibit 3: Architecture, Engineering and Construction Software and Services Market Segmentation in the EMEA Region 2011
    Exhibit 4: Comparison of Software and Services Segments in Architecture, Engineering and Construction Market in the EMEA Region 2011-2015
    Exhibit 5: Architecture, Engineering and Construction Software Segment in the EMEA Region 2011-2015 (US$ billion)
    Exhibit 6: Architecture, Engineering and Construction Services Segment in the EMEA Region 2011-2015 (US$ billion)
    Exhibit 7: Architecture, Engineering and Construction Software and Services Market in the EMEA Region by Vendor Segmentation 2011

    Contact: sales@reportsandreports.com for further details.

    Sunday, 29 July 2012

    World Macroeconomic Composite Forecasts

    The contents of our World Composite Forecasts consist of tables that set forth historical and forecast series for: gross domestic product, per capita GDP, gross fixed capital formation, personal consumption expenditures, population, urban population, households. Forecasts are generally made on a country-by-country basis. The series presented in this publication are developed by the Freedonia Group in-house economics department. These are the same series used by our industry analysts in the preparation of our various industry studies. For each particular series, historical figures are presented for 2001, 2006, and 2011, and forecasts are provided for 2016 and 2021.

    Buy your copy of this report @ http://www.reportsnreports.com/reports/182731-world-macroeconomic-composite-forecasts.html

    Report Details:
    Published: July 2012
    No. of Pages: 116
    Price: Single User License – US$2500


    TABLE OF CONTENTS
    SECTION I -- Gross Domestic Product
    1 World Gross Domestic Product by Region (billion 2010 dollars) 1
    2 North America Gross Domestic Product by Country
    (billion 2010 dollars) 2
    3 Central & South America Gross Domestic Product by Country
    (billion 2010 dollars) 2
    4 Western Europe Gross Domestic Product by Country
    (billion 2010 dollars) 3
    5 Eastern Europe Gross Domestic Product by Country
    (billion 2010 dollars) 4
    6 Africa/Mideast Gross Domestic Product by Country
    (billion 2010 dollars) 5
    7 Asia/Pacific Gross Domestic Product by Country
    (billion 2010 dollars) 6
    SECTION II -- Per Capita Gross Domestic Product
    1 World per Capita GDP by Region (2010 dollars) 7
    2 North America per Capita GDP by Country (2010 dollars) 8
    3 Central & South America per Capita GDP by Country
    (2010 dollars) 8
    4 Western Europe per Capita GDP by Country (2010 dollars) 9
    5 Eastern Europe per Capita GDP by Country (2010 dollars) 10
    6 Africa/Mideast per Capita GDP by Country (2010 dollars) 11
    7 Asia/Pacific per Capita GDP by Country (2010 dollars) 12
    SECTION III -- Gross Fixed Capital Formation
    1 World Gross Fixed Capital Formation by Region
    (billion 2010 dollars) 13
    2 North America Gross Fixed Capital Formation by Country
    (billion 2010 dollars) 14
    3 Central & South America Gross Fixed Capital Formation by
    Country (billion 2010 dollars) 14
    4 Western Europe Gross Fixed Capital Formation by Country
    (billion 2010 dollars) 15
    5 Eastern Europe Gross Fixed Capital Formation by Country
    (billion 2010 dollars) 16
    6 Africa/Mideast Gross Fixed Capital Formation by Country
    (billion 2010 dollars) 17
    7 Asia/Pacific Gross Fixed Capital Formation by Country
    (billion 2010 dollars) 18
    SECTION IV -- Personal Consumption Expenditures
    1 World Personal Consumption Expenditures by Region
    (billion 2010 dollars) 19
    2 North America Personal Consumption Expenditures by Country
    (billion 2010 dollars) 20
    3 Central & South America Personal Consumption Expenditures
    by Country (billion 2010 dollars) 20
    4 Western Europe Personal Consumption Expenditures by Country
    (billion 2010 dollars) 21
    5 Eastern Europe Personal Consumption Expenditures by Country
    (billion 2010 dollars) 22
    6 Africa/Mideast Personal Consumption Expenditures by Country
    (billion 2010 dollars) 23
    7 Asia/Pacific Personal Consumption Expenditures by Country
    (billion 2010 dollars) 24
    SECTION V -- Population
    1 World Population by Region (million persons) 25
    2 North America Population by Country (million persons) 26
    3 Central & Sotuh America Population by Country
    (million persons) 26
    4 Western Europe Population by Country (million persons) 27
    5 Eastern Europe Population by Country (million persons) 28
    6 Africa/Mideast Population by Country (million persons) 29
    7 Asia/Pacific Population by Country (million persons) 30
    SECTION VI -- Urban Population
    1 World Urban Population by Region (million persons) 31
    2 North America Urban Population by Country (million persons) 32
    3 Central & South America Urban Population by Country
    (million persons) 32
    4 Western Europe Urban Population by Country (million persons) 33
    5 Eastern Europe Urban Population by Country (million persons) 34
    6 Africa/Mideast Urban Population by Country (million persons) 35
    7 Asia/Pacific Urban Population by Country (million persons) 36
    SECTION VII -- Households
    1 World Households by Region (million units) 37
    2 North America Households by Country (million units) 38
    3 Central & South America Households by Country
    (million units) 38
    4 Western Europe Households by Country (million units) 39
    5 Eastern Europe Households by Country (million units) 40
    6 Africa/Mideast Households by Country (million units) 41
    7 Asia/Pacific Households by Country (million units) 42
    SECTION VIII -- Regional & Country Tables
    1 World Macroeconomic Forecasts 43
    2 North America Macroeconomic Forecasts 44
    3 Canada Macroeconomic Forecasts 45
    4 Mexico Macroeconomic Forecasts  46
    5 United States Macroeconomic Forecasts 47
    6 Central & South America Macroeconomic Forecasts 48
    7 Argentina Macroeconomic Forecasts 49
    8 Brazil Macroeconomic Forecasts 50
    9 Chile Macroeconomic Forecasts 51
    10 Colombia Macroeconomic Forecasts 52
    11 Peru Macroeconomic Forecasts 53
    12 Venezuela Macroeconomic Forecasts 54
    13 Other Central & South America Macroeconomic Forecasts 55
    14 Western Europe Macroeconomic Forecasts 56
    15 Austria Macroeconomic Forecasts 57
    16 Belgium Macroeconomic Forecasts 58
    17 Denmark Macroeconomic Forecasts 59
    18 Finland Macroeconomic Forecasts 60
    19 France Macroeconomic Forecasts   61
    20 Germany Macroeconomic Forecasts62
    21 Greece Macroeconomic Forecasts63
    22 Ireland Macroeconomic Forecasts 64
    23 Italy Macroeconomic Forecasts 65
    24 Netherlands Macroeconomic Forecasts 66
    25 Norway Macroeconomic Forecasts 67
    26 Portugal Macroeconomic Forecasts 68
    27 Spain Macroeconomic Forecasts 69
    28 Sweden Macroeconomic Forecasts 70
    29 Switzerland Macroeconomic Forecasts 71
    30  United Kingdom Macroeconomic Forecasts 72
    31 Other Western Europe Macroeconomic Forecasts 73
    32 Eastern Europe Macroeconomic Forecasts 74
    33 Bulgaria Macroeconomic Forecasts 75
    34 Czech Republic Macroeconomic Forecasts 76
    35 Hungary Macroeconomic Forecasts 77
    36 Poland Macroeconomic Forecasts 78
    37 Romania Macroeconomic Forecasts   79
    38 Russia Macroeconomic Forecasts80
    39 Slovakia Macroeconomic Forecasts81
    40 Slovenia Macroeconomic Forecasts 82
    41 Ukraine Macroeconomic Forecasts 83
    42 Other Eastern Europe Macroeconomic Forecasts 84
    43 Africa/Mideast Macroeconomic Forecasts 85
    44 Africa Macroeconomic Forecasts 86
    45 Egypt Macroeconomic Forecasts 87
    46 Nigeria Macroeconomic Forecasts 88
    47 South Africa Macroeconomic Forecasts 89
    48 Other Africa Macroeconomic Forecasts 90
    49 Mideast Macroeconomic Forecasts 91
    50 Iran Macroeconomic Forecasts 92
    51 Iraq Macroeconomic Forecasts 93
    52 Israel Macroeconomic Forecasts 94
    53 Saudi Arabia Macroeconomic Forecasts  95
    54 Turkey Macroeconomic Forecasts96
    55 Other Mideast Macroeconomic Forecasts 97
    56 Asia/Pacific Macroeconomic Forecasts 98
    57 Asia Macroeconomic Forecasts 99
    58 China Macroeconomic Forecasts  100
    59 Hong Kong Macroeconomic Forecasts  101
    60 India Macroeconomic Forecasts  102
    61 Indonesia Macroeconomic Forecasts  103
    62 Japan Macroeconomic Forecasts  104
    63 Malaysia Macroeconomic Forecasts  105
    64 Phillipines Macroeconomic Forecasts  106
    65 Singapore Macroeconomic Forecasts  107
    66 South Korea Macroeconomic Forecasts  108
    67 Taiwan Macroeconomic Forecasts  109
    68 Thailand Macroeconomic Forecasts  110
    69 Vietnam Macroeconomic Forecasts  111
    70 Other Asia Macroeconomic Forecasts  112
    71 Pacific Macroeconomic Forecasts  113
    72 Australia Macroeconomic Forecasts  114
    73 New Zealand Macroeconomic Forecasts  115
    74 Other Pacific Macroeconomic Forecasts  116

    For more details Contact:   sales@reportsandreports.com

    Diabetes, Metabolic Syndrome and Cardiovascular Disease

    There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. This TriMark Publications report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future.

    Buy your copy of this report @ http://www.reportsnreports.com/reports/75197-diabetes-metabolic-syndrome-and-cardiovascular-disease.html

    Report Details:
    Published: July 2012
    No. of Pages: 237
    Price: Single User License – US$3400             Corporate User License – US$6800
                                                       Request Sample

    Table of Contents
    1. Overview 9
    1.1 Statement of Report 9
    1.2 About This Report 9
    1.3 Scope of the Report 10
    1.4 Methodology 10
    1.5 Executive Summary 12
    2. Introduction 15
    2.1 Demographics of Diabetes 16
    2.1.1 Worldwide Diabetes 16
    2.1.2 U.S. Diabetes 18
    2.2 Economics of Diabetes 21
    3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 26
    3.1 Pre-Diabetes Syndrome 27
    3.2 Metabolic Syndrome 27
    3.3 Diabetes and Inflammation 32
    3.4 Diagnosis of Diabetes Mellitus 33
    3.5 Progression of Diabetes 33
    3.6 Risk Factors and Diabetes 34
    3.6.1 Obesity 35
    3.6.2 Stress-Induced Hyperglycemia 37
    3.7 Complications and Co-Morbidities in Type 2 Diabetes 37
    3.7.1 Preventing Complications and Co-Morbidities in Diabetes 40
    3.8 Hypoglycemia Resulting From Treatment 42
    3.9 Cardiovascular Disease (CVD) 42
    3.9.1 CVD Facts 42
    3.9.2 Cardiac Care Therapeutics 49
    3.9.2.1 Anti-Hypertensive Drugs 51
    3.9.2.2 Cholesterol Management Drugs 51
    3.9.2.3 Anticoagulants 55
    3.9.3 CVD Diagnostics 55
    4. Pharmaceutical Industry and the Anti-Diabetes Market 58
    4.1 The Worldwide Pharmaceutical Industry 58
    4.1.1 Pharmaceutical R&D Spending by Type, Growth Rate and Expenditure 58
    4.1.2 Global Pharmaceutical Market 60
    4.2 Total Diabetes Drug Market Size and Growth 65
    4.2.1 Sales of Anti-Diabetic Drugs Continue to Rise 68
    4.3 Diabetic Medications Overview 69
    4.3.1 Recent Trends in Diabetic Drug Usage 70
    4.3.2 Market Influence Factors 74
    5. Non-Insulin Anti-Diabetes Products 76
    5.1 Anti-Diabetic Drug Therapy Overview 76
    5.1.1 Sulfonylureas 80
    5.1.2 Meglitinides 81
    5.1.3 Biguanides 82
    5.1.4 Thiazolidinediones (TZDs) 83
    5.1.5 ?-Glucosidase Inhibitors 86
    5.1.6 Incretin Mimetics/Glucagon-Like Peptide (GLP-1) Analogs and Agonists 87
    5.1.6.1 Byetta (Exenatide) 88
    5.1.6.2 Victoza (Liraglutide) 88
    5.1.6.3 Bydureon (exenatide LAR) 88
    5.1.7 Amylin Analog 89
    5.1.8 DPP-IV Inhibitors 89
    5.1.8.1 Januvia (Sitagliptin) 89
    5.1.8.2 Onglyza (Saxagliptin) 90
    5.1.8.3 Tradjenta (Linagliptin) 90
    5.1.9 Combination Therapy 90
    5.1.9.1 Youth With Recent-Onset Type 2 Diabetes Should Be Started on Combination Therapies 92
    5.1.10 Comparisons of the Anti-Diabetes Drugs 92
    5.2 Drivers and Trends 92
    5.2.1 Market Share of Anti-Diabetic Drugs 92
    5.2.2 Forecasts for Anti-Diabetic Drugs 93
    5.2.3 Sales Forecast for the Global Diabetes Market 94
    5.3 The Future 95
    5.3.1 Practice Patterns 95
    5.3.2 New Products in Pipeline 96
    5.3.2.1 Novel GLP-1 Agonists and Analogs 96
    5.3.2.2 Novel DPP-IV Inhibitors 98
    5.3.2.3 Sodium Glucose Cotransporter 2 (SGLT-2) 98
    5.3.2.4 Emerging Non-Insulin Anti-Diabetes Targets and Drugs in the Pipeline 99
    5.3.2.5 Novel Approaches to Finding New Drug Targets 103
    5.4 Anti-Diabetic Drug Patent Expiry 103
    5.5 Regulatory Issues 103
    6. Insulin 104
    6.1 Insulin Markets 104
    6.1.1 Major Players and Market Share 106
    6.1.2 Patent Expirations 107
    6.1.3 Innovation Strategies 108
    6.2 Insulin Therapeutics 108
    6.2.1 Recommendations for Insulin Initiation and Administration 109
    6.2.2 Short-Acting Insulin 111
    6.2.3 Rapid-Acting Insulin 111
    6.2.4 Intermediate-Acting Insulin 113
    6.2.5 Long-Acting Insulin 113
    6.2.6 Long-Acting Insulins in Development 115
    6.2.7 Insulin Mixtures 115
    6.3 Pipeline Insulin 116
    6.4 Non-Invasive Insulin Delivery 116
    6.4.1 Inhaled Insulin 117
    6.4.1.1 A Chronicle of Inhaled Insulins 118
    6.4.2 Oral Insulin 120
    6.4.3 Transdermal Insulin 124
    6.5 Barriers for Non-Injected Insulin 126
    6.6 Patient Potential for Non-Injected Insulin 126
    6.7 Insulin Delivery Devices 126
    6.7.1 Insulin Pens 127
    6.7.2 Injections Aids 132
    6.7.2.1 Automatic Injectors 133
    6.7.2.2 Syringe Magnifiers 134
    6.7.2.3 Injection Ports 134
    6.7.3 Insulin Jet Injectors 134
    6.7.4 Insulin Pumps 135
    6.7.4.1 External Insulin Pumps 136
    6.7.4.2 Insulin Patch Pumps in Development 141
    6.7.4.3 Implantable Insulin Pumps 143
    6.7.4.4 Insulin Pump Market Share 145
    6.7.4.5 Drivers of Demand for Pumps 146
    6.8 Market Forecasts for Insulin Administration Technologies 146
    7. Emerging Anti-Diabetes Technologies and Products 148
    7.1 Projections for the Anti-Diabetes Drug Market 148
    7.2 Artificial Pancreas 151
    7.3 Insulin-Producing Cells 152
    7.3.1 Cell Therapy Companies for Diabetes 153
    7.4 Transplantation Procedures 155
    7.4.1 Pancreatic Transplantation 156
    7.4.1.1 Pancreatic Organ Transplantation 156
    7.4.1.2 Allo-Islet Transplantation 156
    7.4.1.3 Transplantation of Encapsulated Pancreatic Cells 156
    7.4.1.4 Implantation of Genetically Engineered ?-Cells or Embryonic Stem Cells 156
    7.4.2 Current Status 157
    7.5 Gastric Bypass Surgery to Treat Type 2 Diabetes 158
    7.6 Immune Modulators 158
    7.7 Anti-Obesity Drugs to Prevent or Delay Development of Type 2 Diabetes 159
    7.8 Other Anti-Diabetic Therapy Drug Candidates 159
    7.8.1 Lipid Abnormalities 160
    7.8.2 High Blood Pressure 161
    7.8.3 Anticoagulants 162
    7.9 Drugs Used “Off-Label” 163
    7.9.1 Warfarin Sodium 163
    8. Diagnosing Diabetes Using In Vitro Laboratory Tests 164
    8.1 New Diagnostic Guidelines 164
    8.2 Diabetes Tests 165
    8.2.1 Fasting Plasma Glucose (FPG) Test 165
    8.2.2 Glucose Tolerance Test 166
    8.2.3 Test for Glycosylated Hemoglobin 167
    8.2.4 Fructosamine 168
    8.3 Glucose Monitoring 169
    8.3.1 Overview of Market Segment 171
    8.3.2 Competitive Strategies 171
    8.3.3 Analyses of the Current Market Conditions, Competition and Product Mix 173
    8.3.3.1 First-Generation Monitors 174
    8.3.3.2 Second-Generation Monitors 174
    8.3.3.3 Third-Generation SMBG Technologies 174
    8.3.3.4 Product Overview 174
    8.3.4 What Are the Advantages of Using a Continuous Glucose-Monitoring Device? 182
    8.3.5 Minimally-Invasive Continuous Glucose Monitors in Development 184
    8.3.6 Future of Non-Invasive Glucose Technology 184
    8.3.7 Lancets and Lancing Devices 184

    For more details Contact:   sales@reportsandreports.com

    Retailing in India

    The Indian retail market has grown at a double-digit compound annual growth rate over the last five years and was worth an estimated $554bn in 2011. The Indian economy grew throughout the global downturn, with increasing consumer purchasing power bolstering the retail sector. Retailing is now the second highest contributor to India’s gross domestic product.
    Features and benefits
    • Uncover the main opportunities available in the Indian retail market across Clothing, Grocery, Electricals, Health and Beauty and Homewares
    • Understand the size of the Indian market by sector and the growth forecasts to 2015
    • Understand the key financial, cultural, political and logistical reasons that has so far held back the development of modern retail in India
    • Discover which retailers are operating in India and with which local partners
    Highlights
    Confusion reigns over India's FDI policy. Currently international food and grocery retailers are prohibited from entering the Indian market, except through cash and carry wholesale trading, but the government announced plans to lift restrictions in 2011, but then committed an embarrassing u-turn just weeks later.
    The emergence of modern retail started in the major cities of Delhi, Mumbai, and Bangalore, and the satellite towns which have developed around them due to the huge influx of young professionals. Modern retail is concentrated in just a few cities, and premium locations there have already become saturated.
    Employing 8% of the total work force, retail is the second largest employer in the country. The majority of these workers are self-employed, as India has a huge base of traditional retail outlets which are often family-owned. At present, modern retail represents only 5–7% of total retail in India.
    Your key questions answered
    • Why has India's organised retail sector taken so long to develop, and what is continuing to hold it back?
    • How large is the retail opportunity in India, and which sectors are most amenable to entry by foreign retailers?
    • Which international players are operating in India and who do they partner with?

    Buy your copy of this report @ http://www.reportsnreports.com/reports/182415-retailing-in-india.html

    Report Details:
    Published: July 2012
    No. of Pages: 136
    Price: Single User License – US$4495             Corporate User License – US$11238
                                                       Request Sample

    Thursday, 26 July 2012

    Clinical Laboratory Testing Volume 1: IVD Reagents and Instruments Markets

    Clinical laboratory in vitro diagnostic (IVD) testing for reagent and instrument sales is one of the most important sectors of medical care. By all accounts, it is a very mature, large market employing over 100,000 laboratory workers and spawning an industry for reagents and instruments comprised of thousands of companies worldwide. The term clinical laboratory testing usually refers to determining the concentration or activity of a protein, carbohydrate, lipid, electrolyte, enzyme or small molecule in easily collected body fluids such as blood, serum, plasma or urine. However, it is not necessarily limited to these determinations. The purpose of this TriMark Publications report is to describe the specific segments of the global clinical laboratory instrumentation and reagent market. Within this area, the report covers segments that are highly active in terms of innovation and growth. Specifically, this clinical laboratory testing report examines the markets for small lab equipment all the way up to highly-automated, large lab platforms, as well as accessory equipment such as reagents, supplies and manufacturers' original equipment manufacturer (OEM) additional equipment. The emphasis is on companies and products that are actively developing and marketing laboratory analyzer products for the clinical setting, including hospitals, independent labs, physician's offices and miscellaneous clinics. This study concentrates on the clinical laboratory instrumentation industry market segment and the companion reagents sector in the U.S. and around the world. The regional markets and their differences are examined, including in Europe, Asia (Japan, China and India) and the rest of the world (ROW).

    Buy your copy of this report @ http://www.reportsnreports.com/reports/181583-clinical-laboratory-testing-volume-1-ivd-reagents-and-instruments-markets.html


    Report Details:
    Published: July 2012
    No. of Pages: 279
    Price: Single User License – US$3400             Corporate User License – US$6800





    Table of Contents

    1. Overview 8
    1.1 Objectives of the Report 8
    1.2 Methodology 9
    1.3 Scope of the Report 10
    1.4 Executive Summary 11

    2. IVD Industry 19
    2.1 Industry Overview 19
    2.2 IVD Industry Leading Players Comparison and Review 19
    2.2.1 Roche Diagnostics 20
    2.2.2 Abbott Laboratories 22
    2.2.3 Siemens Healthcare Diagnostics 25
    2.2.4 Becton, Dickinson & Co. 26
    2.2.5 Beckman Coulter, Inc. 26
    2.2.6 Ortho-Clinical Diagnostics 31
    2.2.7 bioMérieux 32
    2.2.8 Sysmex 32
    2.2.9 Bio-Rad Laboratories, Inc. 32
    2.2.10 ARKRAY, Inc. 33
    2.2.11 Cytyc Corporation (A Hologic Company) 33
    2.2.12 Gen-Probe, Inc. 33
    2.3 Biotechnology Reagents and Supplies 34
    2.3.1 Vendor Quality Assurance 36
    2.3.2 Partnership Support 36
    2.3.3 Protecting Supply of Raw Materials 37
    2.3.4 Selecting a Second Source for Chemicals 38
    2.3.5 Cost Analysis for Reagent Manufacture 39
    2.3.6 Outsourcing Production of Reagents 39
    2.4 The Fastest Growing IVD Reagent Markets 39
    2.5 High Growth Applications Spur Industry Growth 40
    2.6 Automated Instrument Platforms Evolution 41
    2.7 Reagents and Supplies Market for Clinical Lab Instruments 41
    2.8 Spending for Clinical Laboratory Testing 41
    2.8.1 Reimbursement Pressure 42
    2.8.2 Medicare Part B Spending Trends 43
    2.8.3 Strategies for Revenue Growth 45
    2.8.4 Electronic Health Records 45

    3. IVD Clinical Laboratory Instrument and Reagent Market 46
    3.1 Markets 46
    3.1.1 Global Markets 46
    3.1.2 Global Drivers of Clinical Laboratory Testing 48
    3.1.3 Global Outlook 49
    3.1.4 U.S. Market 50
    3.1.5 European IVD Instruments and Reagents Market 54
    3.1.5.1 German Clinical Laboratory Diagnostic Markets 63
    3.1.5.2 U.K. Clinical Laboratory Testing Diagnostic Product Market 65
    3.1.5.2.1 U.K. Competitive Analysis 65
    3.1.5.2.2 U.K. Market Access 67
    3.1.5.3 French Clinical Laboratory Diagnostic Testing Products Market 67
    3.1.5.4 Italian Clinical Laboratory Diagnostic Products Market 68
    3.1.5.5 Spanish Clinical Laboratory Diagnostic Market 69
    3.1.5.6 Finnish Clinical Laboratory Products Market 70
    3.1.5.7 Turkish Clinical Laboratory Products Market 71
    3.1.5.8 Belgium Clinical Laboratory Diagnostic Products Market 72
    3.1.5.9 Swiss Clinical Laboratory Diagnostic Products Market 72
    3.1.5.10 Dutch Clinical Laboratory Diagnostic Products Market 73
    3.1.5.11 Portuguese Clinical Laboratory Diagnostic Products Market 73
    3.1.5.12 Austrian Clinical Laboratory Diagnostic Products Market 74
    3.1.5.13 Greek Clinical Laboratory Diagnostic Products Market 75
    3.1.5.14 Polish Clinical Laboratory Diagnostic Products Market 75
    3.1.5.15 Romanian Clinical Laboratory Diagnostic Products Market 76
    3.1.5.16 Czech Republic Clinical Laboratory Diagnostic Products Market 77
    3.1.5.17 Swedish Clinical Laboratory Diagnostic Products Market 77
    3.1.5.18 Norwegian Clinical Laboratory Diagnostic Products Market 78
    3.1.5.19 Irish Clinical Laboratory Diagnostic Products Market 78
    3.1.5.20 Hungarian Clinical Laboratory Diagnostic Products Market 79
    3.1.5.21 Bulgarian Clinical Laboratory Diagnostic Products Market 79
    3.1.5.22 Slovakian Clinical Laboratory Diagnostic Products Market 80
    3.1.5.23 Lithuanian Clinical Laboratory Diagnostic Products Market 81
    3.1.5.24 Latvian Clinical Laboratory Diagnostic Products Market 81
    3.1.5.25 Estonian Clinical Laboratory Diagnostic Products Market 82
    3.1.5.26 Slovenian Clinical Laboratory Products Diagnostic Market 82
    3.1.5.27 Russian Clinical Laboratory Diagnostic Products Market 83
    3.1.6 Asian Markets 83
    3.1.6.1 Indian Clinical Laboratory Diagnostic Products Market 85
    3.1.6.1.1 Indian IVD Testing Instrument and Reagents Industry 85
    3.1.6.2 Japanese Clinical Laboratory Testing Products Market 91
    3.1.6.3 Chinese Clinical Laboratory Instrument and Reagent Market 92
    3.1.7 Clinical Laboratory Smaller Country Markets 103
    3.1.7.1 Canadian Clinical Laboratory Market 103
    3.1.7.2 Brazilian Clinical Laboratory Instrument and Reagent Market 103
    3.1.7.3 Australian Clinical Laboratory Instrument and Reagent Market 105
    3.1.8 ROW Clinical Laboratory Testing Instrument and Reagent Market 105
    3.1.9 Overview of Asian Clinical Laboratory Instrument and Reagent Market 106
    3.1.9.1 Singapore 107
    3.1.9.2 Malaysia 109
    3.1.9.3 Thailand 109
    3.1.9.4 Indonesia 110
    3.1.9.5 Philippines 110
    3.1.9.6 South Korea 110
    3.1.9.7 India 111
    3.1.9.8 Hong Kong 111
    3.1.9.9 Taiwan 111
    3.1.10 Overview of the Latin American Diagnostics Market 112
    3.2 Clinical Laboratory Sector 113
    3.2.1 Key Industry Players 113
    3.2.2 Market Specialization 116
    3.2.3 Revenue and Reimbursement 118
    3.2.4 Companies 119
    3.3 Outlook for Clinical Laboratory Testing 120
    3.3.1 Long-term Changes 120
    3.3.2 Market Drivers 121
    3.3.3 The Limits to Growth 123
    3.3.4 Hot Sectors in the IVD Market 123
    3.3.5 Key Technologies 125
    3.3.6 Conclusion 125

    Browse reports related to Healthcare @ http://www.reportsnreports.com/market-research/healthcare/

    Thursday, 12 July 2012

    Bacterial Partnering Terms and Agreements

    The Bacterial Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bacterial partnering deals and agreements entered into by the worlds leading healthcare companies.

    The report provides a detailed understanding and analysis of how and why companies enter bacterial partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors bacterial technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

    Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

    This report contains over 1,000 links to online copies of actual bacterial deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

    The initial chapters of this report provide an orientation of bacterial dealmaking and business activities.

    Chapter 1 provides an introduction to the report.

    Chapter 2 provides an overview of the trends in bacterial dealmaking since 2007 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

    Chapter 3 provides a review of the leading bacterial deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
    Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of bacterial deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

    Chapter 5 provides comprehensive access to all bacterial deals since 2007 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

    Chapter 6 provides a comprehensive directory of all bacterial partnering deals signed and announced since 2007. The chapter is organized by specific infectives therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

    In addition, a comprehensive appendix is provided with each report of all bacterial partnering deals signed and announced since 2007. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

    The report also includes numerous tables and figures that illustrate the trends and activities in bacterial partnering and dealmaking since 2007.

    In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of bacterial technologies and products.


    Buy your copy of this report @ http://www.reportsnreports.com/reports/175339-bacterial-partnering-terms-and-agreements.html



    Report Details:
    Published: July 2012
    No. of Pages: 801
    Price: Single User License – US$1995             Corporate User License – US$2995






    Major points covered in Table of Contents of this report include:

    Executive Summary

    Chapter 1 – Introduction

    Chapter 2 – Trends in bacterial dealmaking

    Chapter 3 – Leading bacterial deals

    Chapter 4 – Bigpharma bacterial deals  

    Chapter 5 – Bacterial partnering contracts directory

    Chapter 6 – Bacterial dealmaking by indication 

    Chapter 7 – Partnering resource center

    Table of Figures

    Browse reports related to Boitechnology @ http://www.reportsnreports.com/market-research/biotechnology/